REVIEW ARTICLE

IgE-based immunotherapy of cancer: challenges and chances

J. Singer & E. Jensen-Jarolim

Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna; Comparative Medicine, Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria

Keywords
AllergoOncology; comparative oncology; IgE; passive immunotherapy.

Abstract
Passive immunotherapy with monoclonal antibodies is an indispensable cornerstone of clinical oncology. Notably, all FDA-approved antibodies comprise the IgG class, although numerous research articles proposed monoclonal antibodies of the IgM, IgG, IgA and IgE classes directed specifically against tumor-associated antigens. In particular, for the IgE isotype class, several recent studies could demonstrate high tumoricidal efficacy. Therefore, this review specifically highlights the latest developments toward IgE-based immunotherapy of cancer. Possible mechanisms and safety aspects of IgE-mediated tumor cell death are discussed with special focus on the attracted immune cells. An outlook is given on how especially comparative oncology could contribute to further developments. Humans and dogs have a highly comparable IgE biology, suggesting that translational AllergoOncology studies in patients with canine cancer could have predictive value for the potential of IgE-based anticancer immunotherapy in human clinical oncology.

The nascent field of AllergoOncology (1, 2) aims to reveal the inverse associations between atopic and malignant diseases, which have in particular been seen in pancreatic cancer, glioma, and childhood leukemia (3–6), to harness allergic mechanisms, such as degranulation of mast cells or basophils and Fcε receptor (FcεR)-mediated immune effects for therapy of cancer.

Cancer research has aimed for decades to overcome tumor tolerance and instead engage the immune system in defense of cancer. Strategies that have been pursued cover basically the whole spectrum of the immune repertoire, such as vaccinations with tumor cells or tumor-associated antigens (TAAs) (8), pulsing of patients’ antigen-presenting cells (9), and activating antitumor immunity via blockade of immune checkpoints (10) to passive immunotherapy with monoclonal antibodies (11). More recent experimental approaches propose to use genetically modified immune cells such as natural killer cells (NK cells) or to engage cytotoxic T cells for identification and vaccination against TAA T-cell epitopes (12) or to engage cytotoxic T cells for identification and vaccination against TAA T-cell epitopes (13).

In spite of promising in vitro and in vivo data of several experimental immunotherapeutic trials and numerous immunotherapeutic approaches in the pipeline (http://www.cancer.gov/clinicaltrials), only two approaches are at the moment of practical relevance in public health: prophylactic vaccines against tumorigenic viruses and passive antibody therapy against tumor-associated antigens.

State of the art: passive immunotherapy of cancer with monoclonal antibodies

Immunotherapy using monoclonal antibodies has found its place in several treatment regimens of malignancies and is at the moment standard of care in, for example, therapy of metastatic breast cancer overexpressing HER-2 (14), metastatic colon cancer overexpressing EGFR (15), or B-cell non-Hodgkin’s lymphoma with autonomous growth of...
CD20-positive B cells (16). More recent approaches even try to modulate the immune system by attacking immune checkpoint inhibitors such as the anti-CTLA-4 (cytotoxic T-lymphocyte antigen-4) antibody ipilimumab, which displayed encouraging results in clinical studies of advanced metastatic melanoma (17–21) or the PD-1 (programmed death-1) (22) targeting antibodies nivolumab and lambrolizumab (23). In particular for lambrolizumab, safety and efficacy could be already demonstrated in patients with advanced metastatic melanoma (24).

The target molecules of the established therapies, however, represent either specific markers of malignantly transformed cells, such as CD20, CD33, or CD52 in hematologic malignancies (25), signal molecules promoting the growth of tumors, such as vascular endothelial growth factor (VEGF) (26), as well as growth factor receptors such as epidermal growth factor receptor (EGFR) (27) or human epidermal growth factor receptor-2 (HER-2) (28). An overview of current FDA-approved monoclonal antibody therapies is depicted in Table 1 (adapted from (29)).

Monoclonal antibodies can thus act in two ways: first by interfering via their Fab regions with binding of growth factor receptors to receptors and thus silencing proliferation signals (30, 31) and second by interacting with immune cells via their Fc domains (32), conferring active tumor cell killing by immune cells via antibody-dependent cell-mediated cytotoxicity (ADCC) (33) and antibody-dependent cell-mediated phagocytosis (ADCP) (34). Moreover, the Fc regions do mediate not only cellular responses, but also humoral immune responses like complement activation (35, 36), ultimately resulting in tumor cell lysis (37, 38).

### Fcγ-receptor-mediated tumor cell killing

As all monoclonal antibodies currently applied in clinical oncology comprise the IgG class ((39), Table 1), attracted immune cells are Fc-gamma-receptor-bearing cells, such as monocytes, macrophages, granulocytes, NK cells (CD32, CD16) (40), and dendritic or Langerhans cells (41). These cells can lead to ADCC (33) or ADCP (34) of tumor cells, furthermore to antigen-processing, transport, and presentation to T cells.

In humans, three groups of Fc gamma receptors were identified: CD64 (FcγRI), CD32 (FcγRIIA, FcγRIIB, FcγRIIC), and CD16 (FcγRIIA, FcγRIIV) (33). They can be divided into activating and inhibiting receptors, depending on the transduction of their signals via immunoreceptor tyrosine-based activation (ITAM) or immunoreceptor tyrosine-inhibitory motifs (ITIMs), respectively. In humans, only FcγRIIB acts inhibitory, whereas all others are activating receptors (42). In early studies with monoclonal antibodies directed against TAAs, different efficacy of murine IgG1 or IgG2a could be observed with respect to ADCC (43). This can be explained by the net result of binding capacities to either activating or inhibitory receptors of the two subclasses (44).

These findings are also valid in humans, but as the nomenclature of IgG subclasses differs between the murine and human IgG system, differently labeled subclasses were investigated. How functionally mouse and human IgGs correspond to each other is depicted in Table 2 (45). When Bruhns et al. investigated the binding capacities of different human IgG subclasses to Fc gamma receptors, they could elucidate that IgG1 and IgG3 can bind to all Fc-gamma receptors and that the inhibitory receptor FcγRIIB has a lower affinity for IgG1, IgG2, and IgG3 than other human FcγRs (i.e. $K_A \sim 2 \times 10^7$M compared with, for example, $K_A \sim 6.5 \times 10^7$M for IgG1 to FcγRI). However, IgG4 has a relatively higher affinity toward FcγRIIB than to FcγRIIA and FcγRIIIA (46), which led to the present understanding of IgG4 being an anti-inflammatory antibody, supporting the immune system in dampening inappropriate inflammatory reactions (47, 48). In particular, in allergy, IgG4 mediates...
allergy-blocking effects (either on the mast cell or at the antigen-presenting cell), accompanied by increased production of IL-10, induction of T-regulatory (Treg) cells (49), and a decrease in symptoms (48). Hence, in malignant disease, the same IgG4-mediated mechanism rendering IL-10 production and Treg induction could likely prompt tumors to escape immunosurveillance. As demonstrated recently, a monoclonal IgG4 directed against chondroitin sulfate proteoglycan 4 (CSPG4), a surface antigen expressed by >80% of malignant melanomas, was ineffective in triggering effector cell-mediated tumor cell killing in vitro. Moreover, when competitively applied with an IgG1 of the same specificity, this IgG4 significantly impaired the tumoricidal impact of anti-CSPG4-IgG1 in a human melanoma xenograft mouse model (50). In line with these findings is another study by Huang et al. (51): when a carcinoembryonic antigen (CEA)-specific IgG4 antibody was converted to IgG1, it significantly gained CDC and ADCC capacity against CEA-expressing tumor cells.

ADCC is one of the most important killing mechanisms harnessed in passive immunotherapy of cancer, underlined by findings that mice deficient for activating receptors FcγRI and FcγRIII were unable to mount protective immune responses against a virus-encoded tumor-specific antigen (52). In contrast, mice deficient for the inhibitory receptor FcγRIIB showed high capacity of ADCC, resulting in tumor growth arrest of subcutaneously grafted BT474 breast cancer cells. Similar effects could be observed in these knockout mice in a pulmonary metastasis model with B16 melanoma cells, where antibody treatment mediated a 100-fold reduction in pulmonary metastasis load compared with untreated animals (53). In humans, binding of IgG1 is affected by a genetic polymorphism of FcγRIIIa on position 158 in the IgG-binding domain (phenylalanine F or valine V, with significantly better binding to FcγRIIIa158V) (54). Accordingly, in a subpopulation analysis of 54 trastuzumab-treated patients with breast cancer, Musolino et al. could depict that individuals homozygous for FcγRIIIa158V/V showed significantly better objective response rates (ORR) and significantly better progression-free survival (PFS) than heterozygous FcγRIIIa158V/F or homozygous for FcγRIIIa158F/F. These findings correlated with significantly higher levels of ADCC in a cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) purified from FcγRIIIa158V/V patients. For other polymorphisms of FcγRIIa (histidine H or arginine R on position 131) and FcγRIIB (isoleucine I or threonine T on position 234), no clinically significant difference could be found but only a trend toward better ORR and longer PFS for the FcγRIIa131H/H genotype (55). Similar effects could be demonstrated in 49 patients with follicular non-Hodgkin’s lymphoma treated with the anti-CD20 IgG1 antibody rituximab (56). Also in a patient cohort with metastatic irinotecan-refractory colorectal cancer, treatment with cetuximab resulted in significantly better outcome rates in FcγRIIa158V/V homozygous patients with respect to PFS; but also this study failed to display a significant difference for the FcγRIIa131 genotype (57).

Another recently discovered regulation mechanism of FcγR function is high copy number variation in their respective gene loci, which is in clear contrast with the gene loci for other Fc receptors (40). It could be shown that there is an association between gene copy number and surface expression of FcγRIIB in neutrophils (58), resulting in enhanced uptake of and adherence to immune complexes (59). Consistently, it was also demonstrated for NK cells from individuals with two or three copies of the FCGR3A gene that also a gene dosage effect for FcγRIIIa receptor levels as well as for ADCC function exists (60). Several recent studies associated copy number variations of FCGRs genes to autoimmune diseases such as systemic lupus erythematosus (SLE), low copy number of FCG3B (61, 62), Sjogren’s syndrome (low copy number of FCG3B) (63), rheumatoid arthritis (low copy number of FCG3B) (64), and antiglomerular basement membrane antibody disease (anti-GBM disease, high copy number of FCGR3A) (65). In particular for SLE and the deletion of FCG3B, the evidence is clear, as a meta-analysis could confirm this association (66). Clearly, such observations should be included in further studies attempting to identify genetic risk factors for autoimmunity (67). However, the effect of these copy number variations concerning tumor immunology and tumor immunotherapy has not been investigated yet and might also contribute to success or failure of IgG-based immunotherapies.

Altogether, epigenetic modification should be considered as a very important factor in all antibody strategies currently applied for immunotherapy of cancer.

**Antibody optimization approaches: trials and pitfalls**

Different approaches to use the documented effects of Fcγ receptor polymorphisms have been pursued therapeutically, for example, by modulation of IgG binding to Fcγ receptors via site-directed mutagenesis, mediating significantly higher rates of tumor cell lysis via ADCC (68).

Biochemical studies could reveal that variations in post-translational glycosylation of constant regions in antibodies’ heavy chains are also of high relevance for binding to different Fcγ receptors (44). So-called glycoengineering of monoclonal antibodies such as the modification of the N-glycosylation pattern at Asn 297 of the IgG heavy chain into reduced fucose content in Fc glycan seems to enhance binding to FcγRIIIa resulting in higher ADCC levels of cancer cells as well as mediating survival benefits in a CEA-overexpressing xenograft model (69). Another chimeric antibody with low fucose content in its Fc region, ublituximab, directed against CD20, had a marked antitumor effect in intracerebral and intraocular mouse models of lymphoma, resulting again in significantly increased survival rates (70).

First examples of glycoengineered antibodies even made their way into clinical testing, like the humanized anti-CD20 antibody, obinutuzumab (GA101). A recently finished phase I study in Japanese patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma exhibited an acceptable safety profile for obinutuzumab, with no dose-limiting toxicities.
observed up to doses of 2000 mg ($c_{\text{max}} = 1910 \pm 156 \, \mu g/ml$), while end-of-treatment response rates were 58% (71). In a different phase I clinical trial, obinutuzumab was administered as maintenance therapy for 2 years, which was again well tolerated (72), leading to current phase III testing of this compound. Another example for a glycoengineered monoclonal antibody in clinical testing is the EGFR-targeting RG7160 (GA201), for which a dose-escalating study showed acceptable safety while exhibiting efficacy in a study cohort of 75 patients with advanced EGFR-positive solid tumors (73).

This also indicates that the expression system for anticancer antibodies is of crucial importance, not just because of efficacy but also for safety aspects. Recently, Platts-Mills et al. observed for cetuximab that it contains galactose-α-1,3-galactose (α-Gal), an immunodominant glyco-epitope derived from SP2/0 cells used as expression system, leading to a risk of angioedema 1–3 h after eating red meat (80). Additionally, there was a striking geographic difference in the prevalence of IgE antibodies against α-Gal with high numbers in the southeast of the USA (Tennessee, Arkansas, and North Carolina) compared with northern or western areas (Massachusetts and California) (74). In a follow-up study, the same group could identify tick bites as the cause of these phenomena. They identified a strong epidemiologic correlation with histories of tick bites and could correlate it with IgE antibodies specific for tick salivary proteins, being α-Gal decorated, which are potent immunogens (81). The expression of α-Gal in red meat explains the potential for associated food-related symptoms.

Overall, oncologists are more and more confronted with hypersensitivity reactions to monoclonal antibodies as well as chemotherapeutics, and pretreatments with antihistamines and cortisone belong to their clinical routine. Specifically for that, precise desensitization protocols have been elaborated (82, 83).

Anticancer IgM, IgA, and IgE

Other optimization approaches aim at engaging different classes of immunoglobulins than IgG. IgM antibodies, physiologically representing the first line of immune response to foreign antigens, could be one option. In particular, it was discovered that the majority of natural antibodies against cancer cells are IgMs, directed against new carbohydrates on post-translationally modified cell surface receptors of malignant cells (84, 85). Although research in this field is young and recombinant IgMs to peptide epitopes not far developed yet, first results are promising. In a model of metastasizing malignant melanoma, a tumor entity with very limited treatment options, Dobroff et al. (86) could demonstrate that monoclonal IgM antibodies reactive to histone 1 can reduce the number of lung nodules in mice.

Generally therapeutic antibodies are directed against epitopes on cell surfaces; however, especially in autoimmune diseases, early studies suggested an uptake of autoantibodies into viable cells (87), leading to apoptosis (88). As many oncoproteins are located intracellular, for example, phosphatase of regenerating liver-3 (PRL-3) or the polyomavirus middle T (mT) oncoprotein, novel targeting approaches via intracellular antibodies have been evolved recently (89). In addition, combination therapies as antibody–drug conjugates (ADCs) could be highly beneficial using these antibodies as vehicles (90).

As IgM antibodies are formed upon the primary encounter with antigens, their affinity is in general low before affinity maturation occurs during an isotype switch from IgM to IgG, IgA, or IgE (45, 91). For monoclonal antibodies against tumor-associated antigens, affinity values to glycan epitopes have been measured in the range of 0.5 nM/l (anti-human embryonic stem cell monoclonal antibody Hesc a 2) (92) to 0.04 nM/l (anti-Sialyl-Lewisα, also known as tumor-associated antigen CA19.9) (93).

IgA, however, either in monomeric (94) or dimeric form (95), can attract a similar panel of effector cells as IgG. NK cells, granulocytes, monocytes, or macrophages express the Fc alpha receptor CD89 (96), but IgA could lead to diverse effector mechanisms (94, 97, 98). IgA can trigger substantial amounts of ADCC via FcRRI, which could be demonstrated elaborately for immature neutrophils, mobilized from the bone marrow upon stimulation with G-CSF (99).

Not only IgA, but also IgE antibodies could be beneficial in this aspect, as IgE is able to mediate high levels of ADCC. Fu et al. (100) could demonstrate that IgE antibodies purified from patients suffering from pancreatic cancer act in vitro cytotoxic against pancreatic cancer cell lines. Additionally, IgE can engage a broad panel of effector cells in tumor defense, with a high cytotoxic and phagocytic potential upon binding to IgE receptors (101), as well as restimulate the immune system via IgE-mediated facilitated antigen uptake and consecutive presentation (102).

Fcε-receptor-mediated tumor cell killing

Fcε receptors comprise, in contrast to Fcγ receptors, only of two classes: FcεRI and FcεRII (CD23), whereupon FcεRI is also termed ‘high-affinity IgE receptor’, and CD23 is known as ‘low-affinity IgE receptor’ (103).

Additionally, galectin-3 has IgE-binding properties, but its entire function in the context of IgE remains to be determined. So far it is known that it can have pro-inflammatory
functions in a mouse asthma model (104), via activating mast cells or basophils by cross-linking receptor-bound IgE (105).

However, both ‘high-affinity’ FcεRI and ‘low-affinity’ CD23 show outstanding affinity to the Fc domains of IgE. For FcεRI, the affinity is in the range of $K_a \sim 10^{10}/M$. CD23 belongs to the C-type (calcium dependent) lectin superfamiy of receptors and displays three lectin domains each having a $K_a \sim 10^{6}–10^{7}/M$ to IgE, thus ranging in the average affinity of FcεRI receptors (106). The avidity of the CD23 trimer increases the affinity to a $K_a \sim 10^{9}/M$ approaching the high affinity of FcεRI (107) and again exceeding the affinity of IgG to its high-affinity receptor FcγRI (106).

Using recombinant IgE antibodies specific for folate receptor-α on ovarian cancer cells, Karagiannis et al. (101) could demonstrate that monocytic killing of tumor cells via ADCC is FcεRI-dependent: blocking of IgE binding to FcεRI on monocytes with monoclonal antibodies or with a soluble α-chain of FcεRI (108), resulting in substantially decreased ADCC. CD23 on monocytic cells, however, which is upregulated upon incubation with IL-4 and IL-13, has the function to clear IgE-antigen complexes from the circulation, and it could be demonstrated that this mechanism can lead to IgE-mediated phagocytosis (ADCP) of tumor cells (107). In this ovarian cancer model, IgE-armed monocytes killed tumor cells via FcεRI-mediated cytotoxicity, followed by CD23-mediated phagocytosis of the remaining cell fragments (101, 108).

Subsequently, side-by-side comparison studies of ADCC and ADCP of the clinically applied anti-HER-2 antibody trastuzumab (Herceptin®, IgG1) and a trastuzumab-like IgE were performed in a breast cancer model, using HER-2-overexpressing cells as targets and the monocytic cell line U937 as effector cells. In this setting, indeed ADCP was the major mechanism of trastuzumab IgG killing, whereas IgE rather triggered monocytes to ADC of tumor cells (34). The same effect could be observed in a recent study where the clinically used antibody cetuximab (Erbitux®, again IgG1) and cetuximab-like IgE were compared in the same ADCC/ADCP assay using this time EGFR-overexpressing A431 cells as targets (Plum et al., unpublished observations). The classical cetuximab (IgG1) mediated phagocytosis, as well as cytotoxicity, concentration dependently. In contrast, cetuximab-like IgE samples caused much less phagocytosis, but significantly higher ADC levels than those of the IgG, in a concentration-dependent manner (109).

**IgE effector cells**

**Eosinophils**

The IgE-mediated tumoricidic mechanisms of monocytic cells are also valid for eosinophilic granulocytes, being among the most classical IgE effector cells. For long, they were just known for their role in allergy or defense of helminthic parasitic infections (110). However, when human eosinophils were purified from venous blood and armed with the antifolate receptor-α-specific IgE described above, ADCC of ovarian cancer cells could be measured. In contrast to killing by monocytes, no phagocytosis of ovarian cancer cells could be determined (108). This could be due to low constitutive expression of CD23 on the surface of eosinophils (111) or lack of CD23 expression on the surface of the eosinophils used in these assays (108). Upon IgE activation, eosinophils can release cytotoxic mediators such as eosinophil cationic protein (ECP), major basic protein (MBP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN). These proteins are well investigated in their cytotoxic action against bacteria, parasites, and viruses, but also respiratory epithelium and cancer cells (112). Synthetic eosinophil-derived neurotoxin, slightly modified by adding four extra residues, has even been studied as a therapeutic agent on its own in Kaposi’s sarcoma in vitro (113, 114). Moreover, eosinophilic granulocytes are able to release TNF-α (115, 116), and it could be demonstrated in a recent study by Legrand et al. (117) that cytotoxic killing of colon cancer cells by eosinophils can be mediated through TNF-α and granzyme A. On the other hand, eosinophils could be ambivalent (118), as they play a role in tissue remodeling in allergic and malignant diseases via mediators such as basic fibroblast growth factor (b-FGF), IL-6, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β) (112).

Eosinophilic peroxidase (EPO) is a haloperoxidase enzyme, whose catalyzed metabolites have been shown to promote oxidative stress and subsequent cell death by apoptosis or necrosis (119). However, even for this eosinophilic enzyme, it could be demonstrated that at noncytotoxic levels, it can drive cell cycle progression and proliferation by signaling via the tumor-associated receptor tyrosine kinase HER-2 (120).

As eosinophils were described to be found in several cancer entities including malignancies of the head and neck region (121), uterine cervix, esophagus, or the gastro-intestinal tract (122), the term ‘tumor-associated tissue eosinophilia’ (TATE) was introduced (123). It is not yet clear what TATE means with regard to prognosis (124); studies in oral squamous cell carcinoma range from higher overall survival (121), across no significant association with respect to tumor differentiation, perineural, vascular, and muscular invasion or locoregional metastasis (125), to unfavorable prognosis for heavy eosinophilia (126, 127, 128).

Only further studies with recombinant antitumor IgG vs IgE antibodies will give a definite picture about the ambivalent role of eosinophils in cancer.

**Mast cells**

The controversy described above is even bigger for another type of IgE effector cells in and around tumors, mast cells (129). Mast cells, named and discovered by Paul Ehrlich in the 19th century (130), have been identified as eminent
players in allergic and anaphylactic reactions of type I hypersensitivity (131). Upon activation via bi- or multivalent antigen-IgE complex binding, which leads to cross-linking of FcεRI, mast cells released within minutes preformed histamine, heparin, and other proteoglycans, several proteases, and cytoplasmic granule-associated cytokines (132), but also a variety of immunomodulatory mediators, such as histamine, serotonin, IL-2, IL-4, IL-21, TNF, G-CSF, and prostaglandins (133, 134). Clinical symptoms of this mediator release include vasodilatation, increase in vascular permeability, contraction of bronchial smooth muscle, mucus secretion, sneezing, itching, and coughing (135). Activation via FcεRI cross-linking also induces the production of cytokines, chemokines, and growth factors, leading to a second wave of allergic symptoms, also called late-phase reactions that typically develop 2–6 h after allergen encounter and peak after 6–9 h (132, 135). Chronic exposure to allergens results in constitutive activation of mast cells leading to tissue remodeling, for example, an increase in mucus-producing goblet cells in the airway epithelium, subepithelial membrane thickening through increased lung collagen deposition, neoangiogenesis, and an increased bronchial smooth muscle mass (132, 136). Similar effects could be demonstrated in a model of human skin, where sonicates of mast cells significantly increased fibroblast proliferation, collagen synthesis, and collagen contraction; surrogates for skin remodeling; and fibrosis (137). These remodeling effects, especially the induction of angiogenesis and neovascularization, are detrimental in malignant diseases (138).

Besides their role in allergy, mast cells are important players in the defense of parasitic infections, such as nematodes and protozoa (139). Furthermore, mast cells contribute to an efficient immune response to bacteria, as it could be demonstrated in an in vivo model of skin infection with Pseudomonas aeruginosa, where mast cell-deficient mice showed increased lesions due to impaired neutrophil recruitment and bacterial clearance (140).

With respect to tumors, mast cells were reported early in tumor-surrounding tissues of different malignant lesions, even by Paul Ehrlich himself. He assumed that mast cells directly fulfill nutritional requirements of malignant tissues (130, 141). This is definitely not the case, but the distinct role of mast cells in oncology is still a matter of debate (142).

One big research topic is how mast cell-derived proteases act on tumor progression. Aromando et al. (143) could demonstrate in a hamster cheek pouch carcinogenesis model that tumor growth was stimulated by mast cell-specific serine protease-6 (MCP-6, tryptase) through activation of protease-activated receptor-2 (PAR-2) on the surface of carcinoma cells. This finding is in line with a previous in vitro study demonstrating that mast cell tryptase stimulates the growth of DLD-1 colon adenocarcinoma cells through PAR-2 and mitogen-activated protein kinase (MAPK)–dependent manner (144). Similar tumor-promoting effects could be demonstrated when investigating mast cell-specific serine protease-4 (MCP-4, chymase), which can activate progelatinase B, thus acting as proangiogenic (145). But when de Souza et al. investigated in a recent study the expression of mast cell proteases MCP-4, MCP-5, MCP-6, and carboxypeptidase A, they could correlate that all proteases increased during tumor progression in a chemically induced skin tumor model, with the exception of MCP-4. Moreover, they could demonstrate that MCP-6 and MCP-7 were able to induce blood vessel formation in vitro (146). Recapitulating these studies, the function of mast cell proteases still remains not fully clear, as it has to be considered that cancerogenesis studies use different chemical compounds for tumor initiation and promotion and different sites, which could also affect the overall susceptibility of the animal to the tumor.

However, there is strong evidence for mast cell-related angiogenesis in tumor growth (138, 145, 146), and also, the multiple immunomodulatory effects of mast cells are intensively investigated, which will clarify the enigmatic role of mast cells in malignant disease.

Basophils

Other major players of Th2-driven immune responses as well as possible potent effector cells of IgE-based immunotherapies are basophils. Basophils share many features with mast cells, both were initially described by Paul Ehrlich, both express FcεRI, and both release histamine upon IgE binding. Whereas mast cells are located primarily in the tissue, basophils can be found in circulation, but with less than 1% of leukocytes in healthy human beings; basophils are the least abundant immune cell population (147). Apart from their contribution to allergic (148) and anaphylactic reactions (149, 150), basophils play a crucial and nonredundant role in defense of endo- and ectoparasites such as helminths (151) or ticks (152).

As basophils are one of the major sources of histamine and anaphylactic mediators in the circulation during an anaphylactic shock (153), one of the major concerns of passive immunotherapy of cancer with monoclonal IgE antibodies is that intravenously applied IgE sensitizes FcεRI on basophils and could potentially be cross-linked by soluble tumor-associated antigens in the circulation, which are shed by tumors. Therefore, it is crucial to target only epitopes, which are not repetitively expressed on the target antigen and do not occur complexed in the circulation. Such antigens, which form tumor-associated molecular patterns (154) on the cell, would solely lead to degranulation in the tissue, but not in the circulation. Tumor-associated antigens that fulfill these requirements are, for example, EGFR and HER-2, for which we could demonstrate that only the dense and rigid antigen display on the surface of cancer cells leads to degranulation of IgE-loaded rat basophilic leukemia cells (RBL-SX38, transfected with human FcεRI), whereas the soluble, monomeric protein shows no effect (34, 109). Rudman et al. could demonstrate in a recent study that patients with ovarian cancer displayed elevated levels of folate receptor-α not only on cancer cells but also in the circulation (up to 35 ng/ml). Still, sera of these patients could neither trigger degranulation of RBL-SX38 cells loaded with antifolate receptor-α-specific IgE, nor activate basophils of healthy donors in an ex vivo
setting again preloaded with antifolate receptor-α IgE (155, 156).

Although this study is very promising, future work in this direction is required, as there are many reports of circulating tumor cells in serum of patients (157–159), and so far it was not investigated how this could affect possible applications of IgE-based immunotherapies.

How to approach translation – from bench to bedside

Clearly, more studies with respect to safety and clinical efficacy are needed to clarify the advantages or complementary effects of IgE-based immunotherapy of cancer (Fig. 1). In particular, side-by-side comparison studies with ‘next-generation’ antibodies such as ‘glycoengineered’ IgG or IgA and IgE antibodies of the same specificity could assess the different potential of antibody classes with particular respect to ADCC and ADCP. There is also great demand for further in vivo studies above preclinical proof-of-concept in mice, given the fact that in vivo efficacy of TAA-specific IgE antibodies has already been demonstrated in severe combined immunodeficiency (SCID) mice with xenografted tumors (101, 160, 161). However, these observed effects do not fully represent the natural picture, which can be expected in cancer patients with spontaneous tumors. To overcome this experimental limitation is not trivial. In contrast to Fcε receptors, which are similarly distributed on human and murine immune cells, the distribution patterns of Fcε receptors differ considerably. Whereas FcεRI is expressed on human mast cells, basophils, eosinophils, monocytes, Langerhans cells, and dendritic cells, in mice, it could be only found on mast cells and basophils (162). Therefore, mouse strains transgenic for human FcεRI have been generated by introducing the human α-chain of FcεRI, which displays the IgE-binding site. Functionality of the receptor could be shown on mast cells (163, 164), as well as monocytes, epidermal Langerhans cells, basophilic and eosinophilic granulocytes (162), making these transgenic mice important models to study the biologic function of IgE (165, 166) and models to investigate the effects and potential of passively applied IgE against grafted tumors (167).

In this context, it is important to note that the dog (Canis lupus familiaris) shares a much more similar FcεRI expression pattern with humans, with functional FcεRI expression not only on mast cells (168), but also on Langerhans cells (169). This results in similar prevalence and pathophysiology of atopic and anaphylactic reactions, underlined by the fact that the historically first described anaphylactic reaction has been observed in a dog model by Paul Jules Portier and Charles Robert Richet (130, 170). In recent years, the value of the dog as a research model has been rediscovered for food allergy and atopic dermatitis (171, 172). As a coincidence, dogs also spontaneously develop tumors, again of striking homology to human disease (173).

**Figure 1** Effects of IgE-based immunotherapy of cancer. (A) Immunotherapy with IgE antibodies can lead to nonimmunologic effects such as growth signal silencing or growth receptor downregulation, due to their epitope specificity. (B) Immunologic effects comprise the attraction of classical antitumor effector cells such as monocytes, macrophages, or NK cells, leading to antibody-dependent cell-mediated cytotoxicity (ADCC) or phagocytosis (ADCP) of cancer cells. Macrophages are also employed to restimulate the immune system, due to their ability for facilitated antigen uptake via Fcε receptors. (C) Moreover, classical IgE effector cells are allured to the site of the tumor, that is, eosinophils, basophils, and mast cells. These cells lead again to ADCC of tumor cells, but release additionally specific mediators, which have been shown to act tumor-inhibiting and/or tumoricidal, such as eosinophil-derived neurotoxin (EDN), tumor necrosis factor-α (TNF-α), or granzyme A. As these cells are also involved in tissue remodeling, known tumor-promoting agents can be released as well, such as basic fibroblast growth factor (b-FGF), platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), or mast cell-specific serine proteases (MCP-4 and MCP-6).
Combining both aspects – IgE pathophysiology and cancer biology – it can thus be anticipated that canine patients would be an ideal natural model, independent of tumor transplants, but developing spontaneous tumors like human patients. Dog patients suffering from cancer simultaneously offer the same IgE effector cell panel, being an ideal model for a potential AllergoOncology trial. They have the same risk of side-effects, but also potentially the same therapeutic benefits as human oncology patients. Such a study could overcome the limitations of the human FcεRI mouse as well as other rodent model organisms, for example, the rat, which although shares IgE receptor biology with humans and is therefore a valuable model in allergy research (174–176), but again would have to get tumors either grafted or artificially induced.

For dogs, however, almost 400 inherited disorders are characterized (177), many of those leading to cancer (178). Moreover, there are several hundred isolated breeds of dogs, and each has a vastly reduced genetic variation. Therefore, several breeds prone to certain malignancies, for example, Golden Retrievers for hemangiosarcoma or Irish Wolfhounds, Siberian Huskies, and Shih Tzus for T-cell lymphoma, could be easily investigated and treated (177).

As dogs live in the same environment like their owners, they share similar risk factors for cancer: age, obesity in early life, and a diet rich of red meat are all associated with higher incidence of mammary carcinoma (179). Also hormonal factors, like reproductive cycles, appear to be similar (180), resulting in expression of estrogen receptors on canine breast cancer cells (181, 182). However, it long seemed that the dog is distinct in its sensitivity to a mammary tumor-promoting effect of progesterin. This was due to the fact that the progesterin induced growth hormone (GH) in the mammary gland (183), a mechanism that could later also be detected in human mammary tumors (184, 185). But it is still not fully clear, how hormone replacement therapy including progesterins changes the risk of breast cancer in women treated with hormone replacement therapy including progesterins (186–188).

Furthermore, it could be demonstrated that these malignancies also share biologic properties, as canine homologues of the tumor-associated-antigens EGFR and HER-2 could be detected on canine mammary carcinoma (189–192). This perception that malignancies in companion dogs and humans occur according to very similar biologic principles has attracted attention because it offers a chance to speed up drug development for both, humans and animals, for now peaking in the establishment of the comparative oncology trial consortium (COTC) by the National Cancer Institute (NCI; http://ccr.cancer.gov/resources/cop/COTC.asp; an overview of the most recent clinical comparative trials initiated by the COTC is depicted in Table 3). In line with this concept, we could show in a recent work that the canine EGFR and HER-2 homologues are susceptible to cetuximab and trastuzumab targeting, leading to growth arrest due to growth signal inhibition (173). Combining both aspects – that dogs resemble similar biologic properties according to the development of malignancies as well as to develop atopic diseases – we suggest the ‘caninization’ of cetuximab and trastuzumab antibodies to canine IgG and IgE antibodies, respectively, in order to more accurately assess side by side the full potential of IgE-based immuno-therapies against cancer and important therapy-related safety issues.

Acknowledgments

This work was supported by grant P 23398-B11 of the Austrian Science Fund (FWF), by SFB F4606-B19, and JS by the CCHD PhD program, FWF project APW01205FW.

Conflicts of interest

Both authors declare that they have no conflicts of interest related to this manuscript.

| Study No. | Name | Status |
|-----------|------|--------|
| COTC001 | Evaluation of RGD Targeted Delivery of Phage Expressing TNF-alpha to Tumor Bearing Dogs | Closed trial |
| COTC003 | Evaluation of the MTOR inhibitor Rapamycin in dogs with osteosarcoma | Closed trial |
| COTC005 | Evaluation of immunocytokine fusion protein in tumor-bearing dogs | Closed trial |
| COTC006 | Evaluation Cryobiopsy Instrumentation And Cellsave Blood Collections In Dogs With Lymphoma | Closed trial |
| COTC007a | A Pilot Study of Topotecan in Dogs with Lymphoma | Closed trial |
| COTC007b | Preclinical Comparison of Three Indenoisoquinolines Candidates in Tumor Bearing Dogs | Open |
| COTC008 | Evaluation of the mTOR inhibitor Rapamycin in Dogs with Metastatic Osteosarcoma | Closed trial |
| COTC010 | Evaluation of two immunocytokine fusion proteins in tumor bearing dogs | Closed trial |
| COTC013 | Evaluation of Orally Administered mTOR inhibitor Rapamycin in Tumor Bearing Dogs | Closed trial |
| COTC016 | A Pilot Study to Assess Feasibility of Tissue Collections and Molecular Profiling for future Comparative Oncology Personalized Medicine Studies | Closed trial |
| COTC018 | Evaluation of a novel anticancer agent in tumor bearing dogs to define its pharmacokinetic profile and biological activity | Open |

Source: http://ccrod.cancer.gov/confluence/display/CCRCOPWeb/Clinical+Trials.
References

1. J. Singer and E. Jensen-Jarolim. IgE-based immunotherapy of cancer. J Clin Oncol 2010;28:4390–4399.

2. Slamon DJ, Godolphin W, Jones LA, Holt PJ, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.

3. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immunol Immunother 2012;61:221–222.

4. Turner MC, Chen Y, Krewski D, Ghadirian P. An overview of the association between allergy and cancer. Int J Cancer 2006;118:3124–3132.

5. Turner MC. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother 2012;61:1493–1510.

6. Schlehofer B, Siegmund B, Linseisen J, Romano E, Ramaiya N, Panagées K, Lawrence DP et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013;119:3687–3695.

7. Ku GY, Yuan J, Page DB, Schroeder SE, Li Y, Zhu Z. Monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoscape. J Clin Oncol 2010;28:4390–4399.

8. Bilusic M, Madan RA. Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am J Ther 2012;19:e172–e181.

9. Boissel-Poile E, Fishman M, Sipuleucel-T: prototype for development of anti-tumor vaccines. Curr Oncol Rep 2011;13:112–119.

10. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–264.

11. Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008;8:1151–1158.

12. Uherek C, Tomm T, Uherek B, Becker S, Schmerle B, Klingemann HG et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002;100:1265–1273.

13. Anderson LD Jr, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother 2011;60:985–997.

14. Comen EA, Fornier MN. Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines. Clin Breast Cancer 2010;10(Suppl 2):S7–S19.

15. Javle M, Hsuheu CT. Recent advances in gastrointestinal oncology-updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol 2010;3:11.

16. Li Y, Zhu Z. Monoclonal antibody-based therapeutics for leukemia. Expert Opin Biol Ther 2007;7:319–330.

17. Weber JS, O’Day S, Urba W, Powderly J, Nicholson G, Yellin M et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950–5956.

18. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bilusic M, Madan RA. Therapeutic cancer vaccines. Curr Oncol Rep 2012;14:1997–2016.

19. Weber JS, O’Day S, Urba W, Powderly J, Nicholson G, Yellin M et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950–5956.

20. Rughani MG, Gupta A, Middleton MR. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Curr Med Chem 2011;18:1651–1657.

21. Lo HW, Hung MC. Nuclear EGFR signaling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006;94:184–188.

22. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.

23. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immunol Immunother 2012;61:221–222.

24. Weber JS, O’Day S, Urba W, Powderly J, Nicholson G, Yellin M et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950–5956.

25. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bilusic M, Madan RA. Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am J Ther 2012;19:e172–e181.

26. Carballido E, Fishman M, Sipuleucel-T: prototype for development of anti-tumor vaccines. Curr Oncol Rep 2011;13:112–119.

27. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–264.

28. Boissel-Poile E, Fishman M, Sipuleucel-T: prototype for development of anti-tumor vaccines. Curr Oncol Rep 2011;13:112–119.

29. Slamon DJ, Godolphin W, Jones LA, Holt PJ, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.

30. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immunol Immunother 2012;61:221–222.

31. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301–311.

32. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158:1–9.

33. Ferris RL, Jaffe EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoscape. J Clin Oncol 2010;28:4390–4399.

34. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 2009;58:915–930.

35. Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 1981;11:1012–1016.

36. Bindon CI, Hale G, Bruggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988;168:127–142.

37. Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 2008;8:759–768.

38. Kim MK, Breitbart CJ, Moon A, Heo J, Lee YK, Cho M et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 2013;5:185ra163.

39. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349–356.

40. Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical conse-
quences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 2009;157:244–254.
41. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005;24:487–499.
42. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24:19–28.
43. Musolino A, Nakdi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789–1796.
44. Bruhns P, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754–758.
45. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies with different isotypes. Cancer Res 1986;46:5592–5598.
46. Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010;125(Suppl 2):S41–S52.
47. Michels V, Goerttsches R, Zett UK. Immunoglobulin basic considerations. J Neurochem 2006;253(Suppl 5):V9–V17.
48. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchar F et al. Impact of FcγRIIA-FcγRII polymorphisms and KRAS mutations on the clinical outcomes of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122–1129.
49. Robinson JI, Carr IM, Cooper DL, Rashid MA, Cooper D et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008;205:1573–1582.
50. Brunnis WB, van Mirre E, Geissler J, von dem Borne AE, de Haas M. FcgammaR3B but not FCGR2A and FCGR2B is associated with susceptibility to autoantibody positive rheumatoid arthritis. Hum Mutat 2012;33:741–749.
51. Willcocks LC, Lyons PA, Claughton MR, Robinson JI, Yang W, Newland SA et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008;205:1573–1582.
52. Kuroki M, Kinugasa T et al. IgG isotype embryonic antigen antibody to increase its conversion of a novel human anti-carcinoembryonic antigen antibody. J Immunol 2002;168:3970–3976.
53. Nimmerjahn F, Ravetch JV. Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113:3716–3725.
54. Aalberse RC, Stapel SO, Schuurman J, Mancardi DA, Fernandez N, Jorieux S et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113:3716–3725.
55. Cartron G, Dacheux L, Salles G, Goupi T, Brunker P, Schmidt C et al. Humanized IgG antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 2009;101:1758–1768.
56. Bengtsson B, Umeda M, Aasland E, Wahren U, Hafstrom L et al. Preclinical study of a glycoengineered anti-human CD20 antibody in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013;54:3657–3665.
57. Nimmerjahn F, Ravetch JV. Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113:3716–3725.
galactose-alpha-1,3-galactose. N Engl J Med 2008;358:1109–1117.
75. Shulman M, Wilde CD, Kohler G. A better cell line for making hybridomas secreting specific antibodies. Nature 1978;276:269–270.
76. Galili U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 2005;83:674–686.
77. Kolke C, Uddin M, Wildman DE, Gray EA, Trucco M, Starzl TE et al. Functionally important glycosyltransferase gain and loss during catarhine primate emergence. Proc Natl Acad Sci USA 2007;104:559–564.
78. Milland J, Sandrin MS. ABO blood group and related antigens, natural antibodies and transplantation. Tissue Antigens 2006;68:459–466.
79. Galili U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses associated with anaphylaxis but not asthma. Am J Respir Crit Care Med 2012;185:723–730.
80. Commins SP, Kelly LA, Ronmark E, James HR, Pochan SL, Peters EJ et al. Galactose-alpha-1,3-galactose-specific IgE is associated with amylasephilia but not asthma. J Allergy Clin Immunol 2013;131:1–11.
81. Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2010;61:1575–1584.
82. Bluth MH. IgE and chemotherapy. Cancer Immunol Immunother 2012;61:1585–1590.
83. Vollmers HP, Brandlein S. Natural antibodies and cancer. N Biotechnol 2009;25:294–298.
84. Schwartz-Albiez R. Naturally occurring and in cancer immunotherapy. Immunol Cell Biol 2005;83:674–686.
85. Schwartz-Albiez R. Naturally occurring and in cancer immunotherapy. Sci Transl Med 2011;3:99ra85.
86. Harper J, Mao S, Stout P, Kamal A. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization. Methods Mol Biol 2013;1045:41–49.
87. Kracker S, Durandy A. Insights into the B cell specific process of immunoglobulin class switch recombination. Immunol Lett 2011;138:97–103.
88. Shoreibah MG, Jackson CL, Price PW, Meagher R, Godwin AK, Cai Q et al. Anti-human embryonic stem cell monoclonal antibody Hesca-2 bonds to a glycán epitope commonly found on carcinomas. Stem Cells Dev 2011;20:515–525.
89. Sawada R, Sun SM, Wu X, Hong F, Ragupathi G, Livingston PO et al. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res 2011;17:1024–1032.
90. Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002;100:4574–4580.
91. Lohse S, Derer S, Beyer T, Klausz K, Peiper M, Leusen HJ et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 2011;186:3770–3778.
92. Monteiro RC. Role of IgA and IgA fc receptors in inflammation. J Clin Immunol 2010;30:1–9.
93. Dechant M, Beyer T, Schneider-Merck T, Weisner P, Peipp M, van de Winkel JG et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 2007;179:2936–2943.
94. Lohse S, Peipp M, Beyer T, Valerius T, Dechant M. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies. Arch Immunol Ther Exp (Warsz) 2010;58:303–312.
95. Otten MA, Rudolph E, Dechant M, Tak CW, Reimers RM, Beenel RH et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 2005;174:5472–5480.
96. Moeckel R. Functional role of IgA and IgA fc receptors in inflammation. J Clin Immunol 2009;29:83–91.
97. Singer J, Braren I. Recombinant IgE antibodies to human ribonuclease and inhibition of the maturon- monocytic protein in oral cancer: a review. Eur J Oral Biol 2011;56:353–358.
98. Newton DL, Rybak SM. Unique recombinant human ribonuclease and inhibition of the maturon- monocytic protein in oral cancer: a review. Eur J Oral Biol 2011;56:353–358.
IgE-based immunotherapy of cancer

J. Singer and E. Jensen-Jarolim
hypersensitivity. Clin Exp Allergy 2011;41:1400–1413.

156. Jensen-Jarolim E, Singer J. Why could pas-
sive immunoglobulin E antibody therapy be safe in clinical oncology? Clin Exp Allergy 2011;41:1337–1340.

157. Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovar-
ian cancer. Gynecol Oncol 2009;112:185–191.

158. Neil J, Buba HA, Erle J, Weber F, Sitek B, Eisenacher M et al. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepato-
telial carcinoma. Transl Oncol 2013;6:420–428.

159. Williams SC. Circulating tumor cells. Proc Natl Acad Sci USA 2013;110:4861.

160. Gould JJ, Mackay GA, Karagiannis SN, O’Toole CM, Marsh PJ, Daniel BE et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999;29:3527–3537.

161. Kershaw MH, Darcy PK, Troupan JA, MacGregor D, Smyth MJ. Tumor-specific IgE-mediated inhibition of human colorec-
tal carcinoma xenograft growth. Oncol Res 1998;10:133–142.

162. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP. Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 1998;8:517–529.

163. Fung-Leung WP, De Sousa-Hitzler J, Ishaque A, Zhou L, Pang J, Ngo K et al. Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E recep-
tor alpha chain respond to human IgE in mast cell degranulation and in allergic re-
jactions. J Exp Med 1996;183:49–56.

164. Dombrowicz D, Brini AT, Flamand V, Hicks E, Snowwaert JN, Kinet JP et al. Anaphylaxis mediated through a human-
ized high affinity IgE receptor. J Immunol 1996;157:1645–1651.

165. Dombrowicz D, Nutten S, Desreumaux P, Neut C, Torpier G, Peeters M et al. Role of the high affinity immunoglobulin E receptor in bacterial translocation and intestinal inflammation. J Exp Med 2001;193:25–34.

166. Plater B, Dehlink E, Turley SJ, Fiebig E. How to connect an IgE-driven response with CTL activity? Cancer Immunol Immunother 2012;61:1521–1525.

167. Daniels TR, Martinez-Maza O, Penichet ML. Animal models for IgE-mediated can-
cer immunotherapy. Cancer Immunol Immunother 2012;61:1535–1546.

168. Brazis P, De Mora F, Ferrer L, Puigde-
mont A. IgE enhances Fc epsilon RI expression and IgE-dependent TNF-alpha release from canine skin mast cells. Vet Immunol Immunopathol 2002;85:205–212.

169. Bonkobara M, Miyake F, Yagihara H, Yamada O, Azakami D, Washizu T et al. Canine epidermal langerhans cells express alpha and gamma but not beta chains of high-affinity IgE receptor. Vet Res Commun 2005;29:499–505.

170. Portier D, Richet C. De l’action anaphylac-
tique de certains venins. Comptes rendus de la Société de biologie 1902;54:170–172.

171. Ermel RW, Kock M, Grifley SM, Reinhart Et al. The atopic dog: a model for food allergy. Lab Anim Sci 1997;47:40–49.

172. Helm RM, Ermel RW, Frick OL. Nonmu-
rine animal models of food allergy. Environ Health Perspect 2003;111:239–244.

173. Singer J, Weichselbaumer M, Stockner T, Helms D, Smyth MJ. Tumor-specific IgE- and IgG-mediated cytotoxicity in vitro. Mol Cell Endocrinol 2002;197:153–165.

174. Mol JA, van Garderen E, Ruttenber GR, Rijnen J. New insights in the molecular mechanism of progestin-induced prolifera-
tion of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. J Steroid Biochem Mol Biol 1996;57:67–71.

175. Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012;104:517–527.

176. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. J Natl Cancer Inst 2013;105:526–535.

177. Schafer C, Brinton LA. The effect of estro-
gen plus progesterone hormone therapy on breast cancer mortality: still unresolved. J Natl Cancer Inst 2013;105:513–514.

178. Gama A, Gartner F, Alves A, Schmitt F. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-
derived cell lines. Am J Vet Res 1996;57:693–696.

179. Dutra AP, Granja NV, Schmitt FC, Cassali GD. c-erbB-2 expression and nuclear pleo-
mosphism in canine mammary tumors. Braz J Med Biol Res 2004;37:1673–1681.

180. Peruzzi D, Mestiti G, Ciliberto G, La Monica N, Aursiseicho L, Telomerase and HER-2/neo as targets of genetic cancer vac-
cines in dogs. Vaccine 2010;28:1201–1208.